What is the appropriate dosing of Monjuvio (Tafasitamab) for weight loss?

From the Research

Dosing of Monjuvio (Tafasitamab)

• The appropriate dosing of Monjuvio (Tafasitamab) for weight loss is not directly addressed in the provided studies 1, 2, 3, 4, 5.
• Study 5 provides information on the dosing of Tafasitamab in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma, where Tafasitamab is administered at a dose of 12 mg/kg.
• However, this study does not investigate the use of Tafasitamab for weight loss, and therefore, the dosing information may not be relevant to this specific indication.
• Studies 2, 3, 4 discuss the dosing of monoclonal antibodies and other medications, but do not provide information on the use of Tafasitamab for weight loss.
• Study 1 investigates the use of topiramate for weight management in children, but does not mention Tafasitamab.

Monjuvio (Tafasitamab) Mechanism and Indications

• Tafasitamab is an Fc-enhanced, humanized, anti-CD19 monoclonal antibody, which suggests that it is used for the treatment of B-cell malignancies, rather than for weight loss 5.
• The provided studies do not support the use of Tafasitamab for weight loss, and the dosing information from study 5 may not be applicable to this indication.

Conclusion on Available Evidence

• There are no research papers among the provided studies that directly address the use of Monjuvio (Tafasitamab) for weight loss or provide relevant dosing information for this indication 1, 2, 3, 4, 5.